Entropy Technologies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Entropy Technologies’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75,908	Closed	-$723K	–	962
2026 Q1	$723K	Buy	75,908 +19,391	+34%	+$151K	0.03%	498
2025 Q4	$441K	Sell	56,517 -11,000	-16%	-$79.5K	0.02%	592
2025 Q3	$512K	Buy	67,517 +46,983	+229%	+$391K	0.04%	510
2025 Q2	$184K	Buy	+20,534	New	+$191K	0.01%	716

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Entropy Technologies's BCRX Position: Q2 2026 in Review

Entropy Technologies sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 75,908 shares — an estimated $723K sold.

Entropy Technologies first reported a position in BCRX in Q2 2025 and held it in 4 quarters. The position peaked at $723K in Q1 2026. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Entropy Technologies reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Entropy Technologies sold 75,908 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $723K.
Entropy Technologies first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Entropy Technologies's BioCryst Pharmaceuticals position peaked at $723K in Q1 2026.
319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.